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Background: Levodopa remains the most effective drug in the treatment of Parkinson’s 
disease. However, long-term administration of levodopa induces motor complications, such as 
levodopa-induced dyskinesia. The mechanisms underlying levodopa-induced dyskinesia are 
not fully understood.
Methods: In this study, we prepared levodopa methyl ester (LDME)/benserazide-loaded 
nanoparticles, which can release LDME and benserazide in a sustained manner. Dyskinesia 
was induced in rats by repeated administration of levodopa then treated with LDME plus 
  benserazide or the same dose of LDME/benserazide-loaded nanoparticles.   Apomorphine-induced 
rotations and abnormal involuntary movements (AIMs) were measured on treatment 
days 1, 5, 10, 15, and 20. In addition, the levels of phosphorylated dopamine- and cyclic adenos-
ine   monophosphate-regulated phosphoprotein of 32 kDa, extracellular signal-regulated kinases 
1/2, and ∆fosB were determined by Western blot. Tau levels were determined by Western blot 
and immunohistochemistry. Dynorphin levels in the striatum and cortex of rats were measured 
using enzyme-linked immunosorbent assay.
Results: Over the course of levodopa treatment, the rats developed abnormal AIMs, clas-
sified as locomotive, axial, orolingual, and forelimb dyskinesia. The degree of reduction of 
apomorphine-induced rotations was comparable in dyskinetic rats treated with LDME plus 
benserazide or LDME/benserazide-loaded nanoparticles. The axial, limb, and orolingual (ALO) 
AIMs of dyskinetic rats treated with LDME/benserazide-loaded nanoparticles were 14 ± 2.5, 
9 ± 2.0, and 10 ± 2.1 on treatment days 10, 15, and 20, respectively, which were significantly 
reduced compared with dyskinetic rats treated with LDME plus benserazide (25 ± 3.7, 27 ± 3.8, 
and 25 ± 3.5, respectively). The locomotive AIMs of dyskinetic rats treated with LDME/
benserazide-loaded nanoparticles were 2.3 ± 0.42, 1.7 ± 0.35, and 1.6 ± 0.37 on treatment days 
10, 15, and 20, respectively, which were also reduced compared with dyskinetic rats treated 
with LDME plus benserazide (4.4 ± 0.85, 4.7 ± 0.95 and 4.8 ± 0.37, respectively). Western blot 
showed that the levels of phosphorylated dopamine- and cyclic adenosine monophosphate-
regulated phosphoprotein of 32 kDa, extracellular signal-regulated kinases 1/2, tau, and ∆fosB 
in dyskinetic rats treated with LDME/benserazide-loaded nanoparticles were 134.6 ± 14.1, 
174.9 ± 15.1, 134.2 ± 19.3, and 320.5 ± 32.8, respectively, which were significantly reduced 
compared with those of dyskinetic rats treated with LDME plus benserazide (210.3 ± 19.7, 
320.8 ± 21.9, 340.4 ± 27.1, and 620.7 ± 48.3, respectively). Immunohistochemistry indicated 
that the level of phosphorylated tau was (7.2 ± 1.1) × 104 in dyskinetic rats treated with LDME/
benserazide-loaded nanoparticles. However, the tau level was only (14.6 ± 2.3) × 104 in LDME 
plus benserazide-treated dyskinetic rats. There was a significant difference between the two 
groups. Enzyme-linked immunosorbent assay showed that dynorphin levels in the striatum and 
cortex of dyskinetic rats treated with LDME/benserazide-loaded nanoparticles were 5.7 ± 1.2 
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and 4.8 ± 0.87, respectively, which were significantly reduced compared with LDME plus benserazide-treated dyskinetic rats (13.3 ± 2.1 
and 8.1 ± 1.1 for the striatum and cortex, respectively).
Conclusion: Results suggest that LDME/benserazide-loaded nanoparticles can be used to reduce the expression of dyskinesia in dys-
kinetic rats.
Keywords: Parkinson’s disease, levodopa-induced dyskinesia, ∆fosB, dopamine, cAMP-regulated phosphoprotein of 32 kDa, extracellular 
signal-regulated kinases 1/2, tau
Chemical Reagent Corporation (Shanghai, People’s 
Republic of China). Citric acid was supplied by Ning 
Pharmaceutical Co, Ltd (Taishan City, People’s Republic 
of China). Methanol was purchased from Jiangsu Yonghua 
Fine Chemical Products Co, Ltd (Jiangsu, People’s Republic 
of China). Poly(lactic-co-glycolic acid) 50/50 3A (47 KDa) 
and polylactic acid (83 KDa) were obtained from Lakeshore 
Biopolymers Inc (Cincinnati, OH). Water was obtained from a 
Milli-Q purification system (Millipore, Molsheim, France).
Preparation of LDME/benserazide-loaded 
nanoparticles
We prepared LDME/benserazide-loaded nanoparticles as 
previously reported.7 Benserazide-loaded nanoparticles were 
prepared according to the water-in-oil-in-water emulsion 
solvent evaporation method. Benserazide was directly added 
to the DCM solution of poly(lactic-co-glycolic acid) 50/50 
3A (47 kDa, 5% wt/wt) and polylactic acid (83 kDa, 7.5% 
wt/wt). The rest of the procedure was the same as the method 
previously reported.7 If the salt or the organic phase was not 
removed completely, nanoparticles would gather together 
and the material would be difficult to inject. When the nano-
particles were initially formed by fast stirring, care had to 
be taken not to let the nanoparticles be exposed to the air. 
If this occurred, the nanoparticles would be destroyed when 
the dichloromethane volatilized quickly. Further, the process 
of microencapsulation was undertaken in dark conditions, to 
avoid light decomposition of the drugs.
Morphological characteristics  
of the nanoparticles
Microsphere shape and surface morphology were estimated 
using scanning electron microscopy. Nanoparticles were 
attached onto a metal stub using double-sided adhesive and 
exposed to gold spray under argon atmosphere for 10 minutes. 
Scanning electron microscopy images were taken using an FEI 
Sirion 200 (Hillsboro, OR) at a sputtering energy of 5 keV .
In vitro release study
Twenty milligrams of nanoparticles were accurately 
weighed then dispersed in 1 mL of dissolution medium 
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative 
disorder often observed in older patients. Levodopa has been 
used to treat the disease for many years. Although levodopa 
is effective for treating the motor disturbance associated with 
Parkinson’s disease,1 long-term levodopa therapy is known to 
cause levodopa-induced dyskinesia (LID).2,3 The pathology 
of LID is poorly understood and, once established, it is dif-
ficult to treat. Numerous studies have shown that continuous 
dopamine stimulation can be used to reduce the expression 
of LID.4–6 Continuous dopamine stimulation can ameliorate 
the neuron adaptations in the striata of 6-hydroxydopamine 
(6-OHDA)-lesioned rats. We recently reported that levodopa 
methyl ester (LDME)/benserazide-loaded nanoparticles can 
be used to treat PD motor symptoms and reduce the expres-
sion of LID in a rat model of PD.7 However, whether LDME/
benserazide-loaded nanoparticles can be used to ameliorate 
established levodopa-induced dyskinesia in rats is not well 
understood. In this study, dyskinesia was induced in rats by 
repeated administration of levodopa. Then, the effects of 
LDME/benserazide-loaded nanoparticles on abnormal invol-
untary movements (AIMs) and the levels of phosphorylated 
dopamine- and cyclic adenosine monophosphate-regulated 
phosphoprotein of 32 kDa (p-DARPP-32) at threonine 34, 
phosphorylated extracellular signal-regulated kinases 1/2 
(p-ERK1/2), ∆fosB, and dynorphin, which are closely associ-
ated with LID in rats, were investigated. Moreover, a recent 
study has shown that phosphorylated tau (p-tau) might be 
associated with LID.8 However, it remains unknown whether 
continuous dopamine stimulation can affect the phospho-
rylation of tau in PD rats. To this end, whether LDME/
benserazide-loaded nanoparticles can reduce the expression 
of p-tau in dyskinetic rats was also investigated.
Materials and methods
Materials
LDME and benserazide hydrochloride were purchased from 
Sigma (St Louis, MO). Polyvinyl alcohol, dichloromethane 
(DCM), phosphoric acid, potassium dihydrogen phosphate, 
sodium phosphate dibasic anhydrous, and sodium chloride 
(NaCl) were obtained from the Chinese Medicine Group 
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(0.5835 g Na2HPO4 and 1.5264 g citrate acid per 100 mL 
of distilled water, approximate pH of 3.5). The solution was 
rotated in a constant-temperature rotating basket (HZ-8812S, 
Taichang Scientific Education Apparatus Factory, Jiangsu, 
People’s Republic of China; 37°C, 50 rpm). Samples were 
withdrawn at specified time intervals for analysis and replaced 
with equivalent volumes of fresh dissolution medium. LDME 
and benserazide concentrations were measured using a high-
performance liquid chromatograph (WondaSil C18-WR, 
Shimadzu Corp, Kyoto, Japan).
LDME was analyzed at 280 nm; the mobile phase 
consisted of water:methanol = 80:20 (pH was adjusted 
to 3.5 using phosphoric acid). Benserazide was analyzed 
at 220 nm; the mobile phase consisted of trichloroacetic 
acid:methanol:water = 1:20:100. The concentrations of the 
samples were calculated using standard curves made in 
advance.
Determination of encapsulation efficiency
After 20 days of in vitro release, the drug in the dissolu-
tion medium could not be detected by high-performance 
liquid chromatography (HPLC). Then the nanoparticles 
(20 mg) were dissolved in 0.5 mL of DCM in a vortex 
oscillator and the residual drug in the DCM solution was 
extracted three times using 0.5 mL dissolution medium. The 
residual drug was also examined by HPLC under the same 
conditions mentioned. The release amount in vitro and the 
residual drug amount were summed to calculate the total 
drug amount loaded in the nanoparticles. Encapsulation 
efficiency was calculated according to the following 
formula:
Encapsulation efficiency
Weight of encapsulated drug
Weight
=
   of the total amount of drug used for encapsulation
100% ×   (1)
In vivo release study
After analyzing the results of in vitro release, the formula-
tion with the longest release time and an acceptable initial 
burst was chosen for the in vivo study. Following this, 
four healthy male rats each weighing approximately 500 g 
were subcutaneously injected with weighed nanoparticles 
dispersed in a liquid of suitable viscosity (60 mg mannitol 
and 50 mg sodium carboxymethylcellulose per 10 mL of 
injectable water, 1 g nanoparticles dispersed in approxi-
mately 30 mL liquid). The amount of nanoparticles injected 
is given 500 mg.
Blood samples were collected from rats’ tails at speci-
fied time intervals then centrifuged (5000 rpm, 5 minutes). 
Afterward, plasma proteins were removed by adding 
methanol (chromatographically pure) and centrifuging again 
(10,000 rpm, 20 minutes). Analysis of the samples was also 
carried out using HPLC under the same conditions previ-
ously mentioned. The concentration of samples was calcu-
lated by standard curves generated from drugs dissolved in 
methanol (chromatographically pure).
All protocols involving animals were approved by the 
Institutional Review Board of Xinhua Hospital and were 
performed according to the guidelines of the National Insti-
tutes of Health for the care and use of laboratory animals 
(NIH publication No. 80-23).
6-hydroxydopamine lesions
All animals received injections totaling 8 µg 6-OHDA 
(Sigma, St Louis, MO). Coordinates were calculated using 
the rat brain atlas as follows: anterior–posterior: −4.4 mm, 
medial–lateral: −1.2 mm, dorsal–ventral: −7.8 mm.9 The tooth 
bar was set to −2.4 mm. One week after the injections, rats 
that exhibited stable apomorphine-induced rotational asym-
metry of at least seven full turns per minute away from the 
lesioned side were selected for the following experiment.
Treatment
All valid PD rats were administrated with levodopa to induce 
expression of  LID. Then all dyskinetic rats (AIMs score . 8) 
were divided into two groups: levodopa + levodopa (n = 14) 
and levodopa + nanoparticle (n = 14). Rats in the 
levodopa + levodopa group were treated with LDME (6 mg/kg, 
subcutaneously) plus benserazide (15 mg/kg, subcutane-
ously) daily for 3 weeks. With the assumption that LDME/
benserazide-loaded biodegradable nanoparticles would 
gradually release the drug over at least 1 week, rats in the 
levodopa + nanoparticle group were treated with subcuta-
neous LDME/benserazide-loaded nanoparticles contain-
ing LDME (6 mg/kg, subcutaneously) plus benserazide 
(15 mg/kg, subcutaneously) once per week for 3 weeks. 
In addition, rats in the PD group (n = 14) and sham group 
(n = 14, given sham-6-OHDA injections without expressing 
PD symptoms) were treated with a subcutaneous vehicle 
daily for 3 weeks.
Apomorphine-induced rotations
On test days, after administration of apomorphine (0.5 mg/kg, 
intraperitoneally), apomorphine-induced rotations were 
measured for 30 minutes.
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Measurement of abnormal involuntary 
movements
Rats were monitored for AIMs using a procedure similar 
to that described previously.10 On test days, rats were 
individually placed in plastic trays 5 minutes before drug 
treatment. Following injections, each rat was assessed for 
exhibition of ALO and locomotive movements. At 20-minute 
intervals (ie, 20, 40, 60, 80 minutes, etc), AIMs were rated for 
60 seconds for each rat for a total of 2 hours, during which a 
severity score between 0 and 4 was assigned for each AIMs 
category. For each AIMs category, the scores for each time 
point were summed.
Western blot
Striatal tissues were homogenized (1:10 wt/vol) in 20 mM 
tris(hydroxymethyl)aminomethane hydrochloride (pH 7.4), 
containing 1 mM NaF, 150 mM NaCl, 1% TritonTM X-100 
(Sigma-Aldrich, St Louis, MO), fresh protease inhibitor 
cocktail (CalBiochem, La Jolla, CA), and 100 µM phe-
nylmethylsulfonyl fluoride. Cytosols were prepared by 
centrifugation at 12,000 g for 10 minutes at 4°C. Samples 
containing 40 µg protein were separated on a 10% sodium 
dodecyl sulphate-polyacrylamide gel and electrophoretically 
transferred to polyvinylidene fluoride membranes (Bio-Rad, 
Hercules, CA) in tris-glycine transfer buffer. Membranes 
were then blocked in instant nonfat dried milk (5% wt/vol) 
for 2 hours at room temperature and incubated with primary 
antibodies corresponding to DARPP-32, ERK1/2, ∆fosB, or 
tau (1:500; Transduction Laboratories, Lexington, KY) at 
4°C overnight. The membranes were subsequently washed 
with TBST (50 mM tris(hydroxymethyl)aminomethane 
hydrochloride [pH 7.5], 150 mM NaCl, 0.05% Tween® 20 
[Sigma-Aldrich]) and incubated with secondary horserad-
ish peroxidase-conjugated immunoglobulin G for 1 hour at 
room temperature. Immunoreactive proteins were visualized 
by LumiGLO (Cell Signaling Technology, Beverly, MA) 
chemiluminescent reagent and peroxide. The light-emitting 
bands were detected with X-ray films.
Immunohistochemistry
Rats were sacrificed by deep anesthesia using 3%   phenobarbital 
and their ascending aortas were perfused with cold phosphate-
buffered saline (PBS), followed by 4%   paraformaldehyde. 
Brains were removed and post-fixed in the same fixative for 
24 hours, followed by 30% sucrose. Six series of coronal 
sections were cut at a thickness of 30 µm using a freezing 
microtome (Leica 1900, Leica Microsystems GmbH, Wetzlar, 
Germany) and stored at −20°C until used. After endogenous 
peroxidase was quenched with 3% hydrogen peroxide, brain 
sections were preincubated in 10% normal horse serum/0.2% 
Triton X-100/0.1 M PBS for 1 hour at room temperature. The 
sections were incubated with antibodies against tau and p-tau 
(1:500; Abcam, Cambridge, MA) in 0.1 M PBS containing 
1% normal horse serum. The sections were then incubated 
for 1 hour at room temperature with biotinylated anti-mouse 
immunoglobulin G (1:200; Vector Labs, Burlingame, CA). 
The bound antibodies were visualized using an avidin-biotin-
peroxidase complex system (Vectastain ABC Elite Kit, Vector 
Labs), with 3,39-diaminobenzidine as the chromogen.
Enzyme-linked immunosorbent  
assay (ELISA)
Striatal supernatants of rats were measured for dynorphin 
concentrations using a sandwich ELISA procedure   according 
to the manufacturer’s instructions (Cusabio Biotech Co, Ltd, 
Wuhan, People’s Republic of China). Values were converted 
to pg/mL with reference to a standard curve that was assayed 
in parallel to the test samples. The range of values detected 
by this assay for dynorphin was 0.32–20 ng/mL.
Statistics
Data were expressed as the mean ± standard deviation. Behav-
ioral analyses were performed using a t-test. Other statistical 
analyses were performed using one-way analysis of variance, 
followed by Dunnett’s t-test. P values ,0.05 were considered 
statistically significant differences.
Results
Nanoparticle morphology
The mean particle size of the nanoparticles was approxi-
mately 500 nm and the surface was smooth, with no evident 
drug particles embedded, which helped to reduce the initial 
burst. After freeze-drying, the nanoparticles turned into well-
dispersed powder (Figure 1).
Figure 1 Scanning electron microscopy of the nanoparticles.
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In vitro release
Figures 2 and 3 show the two drugs sustained release within 
approximately 3 weeks, with the initial burst rate only 18.3% 
and 30% total drug loading in the first 2 days. The two drug-
loaded nanoparticles were preferred to continue the experi-
ment in vivo due to its more stable release.
Encapsulation efficiency
Encapsulation efficiency was calculated using Equation 1. The 
encapsulation efficiency of LDME was 60.15% ± 4.2%, lower 
than that of benserazide (62.87% ± 6.9%). Encapsulation 
efficiency is mainly affected by the way the nanoparticles 
are prepared; for example, the spray drying process always 
produces a much higher encapsulation rate. In our study, 
encapsulation efficiency was influenced by various param-
eters, such as pH value when the nanoparticles were formed 
by fast stirring and the pressure when the organic phase 
volatilized.
In vivo release
Plasma concentration of LDME reached a high stable level 
in the first 14 days then reverted to a relatively normal level 
until nearly 3 weeks had passed (Figure 4).
The release profile of benserazide was similar to that 
of LDME, since they share the same release mechanism in 
vivo (Figure 5).
Both LDME and benserazide showed longer sustained 
release in vivo than in in vitro, probably because, in in vitro, 
the dissolution medium was refreshed frequently, which 
provided sink conditions that accelerated the diffusion driven 
by concentration difference, while the drugs in vivo tended to 
accumulate at the nanoparticles’ position much longer.
Apomorphine-induced rotations
As shown in Figure 6, after apomorphine   administration, 
apomorphine-induced rotations in rats decreased   following 
administration of levodopa plus benserazide (ie, in the 
levodopa + levodopa group) or administration of LDME/
benserazide-loaded nanoparticles (ie, in the levodopa + nano-
particle group). More importantly, the degree of reduction 
of apomorphine-induced rotations was comparable in the 
two groups. The data showed that the degree of alleviation 
of parkinsonism in the two groups was comparable.
Effect of administration of LDME/
benserazide-loaded nanoparticles  
on AIMs in dyskinetic rats
After administration of levodopa, dyskinetic rats showed 
increased AIMs. This increase indicated that levodopa 
can increase the symptoms of dyskinetic rats. However, 
administration of LDME/benserazide-loaded nanoparticles 
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Figure 2 Levodopa methyl ester release in vitro.
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Figure 3 Benserazide release in vitro.
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Figure 4 Levodopa methyl ester release in vivo.
Note: Nanoparticles injected = 1 g.
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Figure 5 Benserazide release in vivo.
Note: Nanoparticles injected = 1 g.
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markedly reduced AIMs produced by levodopa/benserazide 
in dyskinetic rats that had undergone 3-week long dyskinesia 
priming (Figure 7).
Effect of administration of LDME/
benserazide-loaded nanoparticles  
on phosphorylated levels of DARPP-32 
and ERK1/2 and ∆fosB in dyskinetic rats
As shown in Figure 8A and B, administration of LDME plus 
benserazide significantly increased the levels of p-DARPP-32 
and p-ERK1/2 in dyskinetic rats. In contrast, administration 
of LDME/benserazide-loaded nanoparticles reduced the 
levels of p-DARPP-32 and p-ERK1/2 in dyskinetic rats. 
No significance difference in total DARPP-32 and ERK1/2 
was observed in dyskinetic rats treated with LDME plus 
benserazide or LDME/benserazide-loaded nanoparticles. 
∆fosB levels were determined by Western blot. Upon analy-
sis, we found that administration of LDME plus benseraz-
ide induced increased levels of ∆fosB in dyskinetic rats. 
However, administration of LDME/benserazide-loaded 
nanoparticles prevented the increase of ∆fosB in dyskinetic 
rats (Figure 8C).
Effect of administration of LDME/
benserazide-loaded nanoparticles  
on phosphorylated levels  
of tau protein in dyskinetic rats
As shown in Figure 9B, administration of LDME/ 
benserazide-loaded nanoparticles led to a similar pattern of 
changes in p-tau compared with p-DARPP-32, p-ERK1/2, 
and ∆fosB in dyskinetic rats. In general, levodopa treatment 
produced increased levels of p-tau in dyskinetic rats 
treated with levodopa when compared with 6-OHDA-
lesioned rats treated with the vehicle. However, no obvious 
increase of p-tau was seen in LDME/benserazide-loaded 
  nanoparticle-treated d  yskinetic rats compared with 
vehicle-treated 6-OHDA-lesioned rats. Immunohistochem-
istry confirmed the results measured by Western blot 
(Figure 9A).
Effect of administration of LDME/
benserazide-loaded nanoparticles  
on dynorphin levels of in dyskinetic rats
The levels of dynorphin in the striatum and cortex of 
rats were analyzed by ELISA. As shown in Figure 10, 
  dynorphin levels were reduced in the striatum and cortex 
of PD rats. After repeated administration of LDME plus 
b  enserazide, dynorphin levels were increased in the striatum 
and cortex of dyskinetic rats compared with vehicle-treated 
6-OHDA-lesioned rats. In contrast, administration of LDME/ 
benserazide-loaded nanoparticles prevented the increase of 
dynorphin in dyskinetic rats.
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Discussion
Levodopa-induced dyskinesia is the main side effect of 
levodopa in the treatment of Parkinson’s disease. It has been 
demonstrated that continuous dopamine stimulation and 
long-term levodopa are useful in the treatment of LID.11,12 
However, the mechanism underlying this is not understood. 
In this study, LID was induced in a rat model of PD by 
repeated administration of levodopa. We found that ALO 
AIMs gradually developed during chronic treatment with 
levodopa. Then LDME/benserazide-loaded nanoparticles, 
which can release levodopa and benserazide in a sustained 
manner, were used to treat rats with LID. We found that 
LDME plus benserazide-treated dyskinetic rats showed 
sustained AIM scores. However, administration of LDME/
benserazide-loaded nanoparticles can ameliorate LID in 
established LID rats, which was evidenced by decreased 
AIMs observed in LID rats. More importantly, molecular 
makers of LID were reduced in dyskinetic rats. This indicates 
that LDME/benserazide-loaded nanoparticles can be used to 
reduce the expression of LID in rats.
Phosphorylation is indicative of ERK1/2 activation, 
which triggers a molecular cascade that frequently results 
in immediate early gene expression.13–15 The increases in 
ERK1/2 activation and ∆fosB expression after chronic 
treatment appear to be specific to the supersensitive response 
to levodopa induced by the dopaminergic lesion because 
neither acute nor chronic levodopa treatment activates 
ERK1/2 phosphorylation or increases ∆fosB expression 
in the dopamine-intact striatum.16,17 Phosphorylation and 
activation of ERK1/2 and subsequent translocation to 
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Figure 8 Effect of administration of LDME/benserazide-loaded nanoparticles on levels of p-DARPP-32, p-ERK1/2, and ∆fosB. Protein levels were determined by Western blot 
using proteins extracted from the striatum of the rat brain. The results indicate that administration of LDME plus benserazide induced increased levels of p-DARPP-32 (A), 
p-ERK1/2 (B), and ∆fosB (C) in dyskinetic rats. Reduced levels of these molecules were found in – dyskinetic rats treated with LDME/benserazide-loaded nanoparticles.
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the nucleus has been shown to be involved in synaptic 
plasticity leading to long-term potentiation.18 Similarly, 
phosphorylation of ERK1/2 and the subsequent long-lasting 
overexpression of ∆fosB after levodopa treatment may 
mediate long-term potentiation at glutamatergic synapses 
in the striatum.16,19 It has been suggested that hyperactivity in 
the glutamatergic corticostriatal pathway is involved in the 
development or expression of dyskinesias.20–22 DARPP-32 
is known to play a critical role in D1R-mediated 
transmission.23–25 Studies have shown that DARPP-32 is 
one important mediator of cAMP signaling. PKA-catalyzed 
phosphorylation at threonine 34 leads DARPP-32 to be an 
inhibitor of protein phosphatase-1.26 In turn, this prevents 
dephosphorylation of downstream target proteins regulated 
by PKA, thereby intensifying cAMP-mediated responses. 
In this study, we found that chronic levodopa treatment 
induced increased levels of p-DARPP-32, p-ERK1/2 
and ∆fosB. Meanwhile, levodopa-treated dyskinetic rats 
showed high AIM scores. This indicated that hyperactivity 
of neurons in the striata of PD rats can be induced by 
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Figure 10 Effect of administration of LDME/benserazide-loaded nanoparticles on 
dynorphin levels in the striatum (A) and cortex (B) of dyskinetic rats. The levels 
of dynorphin were evaluated by ELISA. The results showed that after repeated 
administration  of  LDME  plus  benserazide,  dynorphin  increased  significantly  in 
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decreased dynorphin levels in dyskinetic rats.
Notes: (A) *P , 0.01 versus sham; #P , 0.01 versus PD group; **P , 0.01 versus 
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was performed using one-way analysis of variance , followed by Dunnett’s t-test.
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chronic levodopa treatment. In contrast, administration of 
LDME/benserazide-loaded nanoparticles reduced levels of 
p-DARPP-32, p-ERK1/2, and ∆fosB. This indicates that 
administration of LDME/benserazide-loaded nanoparticles 
can reduce the hyperactivity of neuron in striata of 
LID rats. Previous studies have shown that long-term 
administration of levodopa can lead to the phosphorylation 
of tau in 6-OHDA lesioned rats.8 This indicates that p-tau 
may play a role in the expression of LID. In this study, 
we found that after repeated administration of levodopa. 
Increased levels of p-tau were observed in dyskinetic rats, 
which was consistent with our previous study.8 However, 
administration of LDME/benserazide-loaded nanoparticles 
prevented the increase of p-tau in dyskinetic rats while 
reducing the development of dyskinesia. This suggests that 
preventing the phosphorylation of tau might be helpful in 
reducing the emergence of LID in rats.
An association between LID and an upregulation of 
striatal preprodynorphin mRNA in 6-OHDA-lesioned rats 
has been widely described.27 Reducing the overexpression of 
dynorphin can attenuate the expression of LID. In animals, 
some agents have been proven to attenuate the expression of 
LID by reducing dynorphin levels.28 In this study, we found 
that levodopa induced increased levels of dynorphin in the 
striatum and cortex of dyskinetic rats, which confirmed the 
previous study. However, administration of LDME/benser-
azide-loaded nanoparticles reduced the development of LID 
in rats by preventing the increase of dynorphin induced by 
levodopa.
Conclusion
We found that levodopa treatment can cause the expression 
of LID in rats. With the expression of dyskinesia, increased 
levels of p-DARPP-32, p-ERK1/2, ∆fosB, tau, and dynorphin 
were seen in dyskinetic rats. However, administration of 
LDME/benserazide-loaded nanoparticles reduced the expres-
sion of LID while preventing the increase of molecules that 
are closely associated with the development of dyskinesia 
in dyskinetic rats.
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